- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05365659
진행성 B 세포 비호지킨 림프종 환자의 IKS03
진행성 B 세포 비호지킨 림프종(NHL) 환자에서 IKS03의 안전성, 내약성, 최대 허용 용량 및 예비 항신생물 활성을 결정하기 위한 1상 코호트 용량 증량 및 확장 시험
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
연구 개요
상세 설명
The study will consist of 2 parts: dose-escalation (Part I) and dose-expansion (Part II). The dose-escalation part (Part I) of the study is to evaluate the safety and tolerability of increasing dose levels of IKS03 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part II) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of IKS03 at the RP2D.
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: David Browning
- 전화번호: 615-975-7776
- 이메일: david.browning@iksuda.com
연구 장소
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201
- 빼는
- University of Maryland Baltimore
-
-
-
-
-
Badalona, 스페인
- 모병
- Institut Catala D'Oncologia
-
연락하다:
- Mireia Franch-Sarto, M.D.
-
수석 연구원:
- Mireia Franch-Sarto, M.D.
-
Madrid, 스페인
- 모병
- Hospital Universitario Quironsalud Madrid
-
연락하다:
- Maria del Carmen Martinez-Chamorro, M.D.
-
수석 연구원:
- Maria del Carmen Martinez-Chamorro, M.D.
-
Salamanca, 스페인
- 모병
- Hospital Clinico Universitario de Salamanca
-
연락하다:
- Alejandro Martin Garcia-Sancho, M.D.
-
수석 연구원:
- Alejandro Martin Garcia-Sancho, M.D.
-
-
-
-
-
Candiolo, 이탈리아
- 모병
- Istituto Nazionale Oncologico Candiolo
-
연락하다:
- Umberto Vitolo, M.D.
-
수석 연구원:
- Umberto Vitolo, M.D.
-
Milan, 이탈리아
- 모병
- Istituto Europeo di Oncologia
-
연락하다:
- Enrico Derenzini, M.D.
-
수석 연구원:
- Enrico Derenzini, M.D.
-
Milan, 이탈리아
- 모병
- Istituto Europeo Clinico Humanitas
-
연락하다:
- Carmelo Carlo-Stella, M.D.
-
수석 연구원:
- Carmelo Carlo-Stella, M.D.
-
Milan, 이탈리아
- 모병
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele
-
연락하다:
- Andres Jose Maria Ferreri, M.D.
-
수석 연구원:
- Andres Jose Maria Ferreri, M.D.
-
-
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3T 1E2
- 모병
- Jewish General Hospital
-
수석 연구원:
- Sarit Assouline, MD
-
연락하다:
- Sarit Assouline, MD
-
-
-
-
New South Wales
-
Westmead, New South Wales, 호주, 2145
- 모병
- Westmead Hospital
-
수석 연구원:
- Amanda Johnston, MD
-
-
South Australia
-
Adelaide, South Australia, 호주
- 모병
- Royal Adelaide Hospital
-
연락하다:
- Pratyush Giri, MBBS
-
수석 연구원:
- Pratyush Giri, MBBS
-
-
Tasmania
-
Hobart, Tasmania, 호주, 7000
- 모병
- Royal Hobart Hospital
-
수석 연구원:
- Rosemary Harrup, MD
-
-
Western Australia
-
Perth, Western Australia, 호주
- 모병
- Linear Clinical Research
-
연락하다:
- Katharine Lewis, MD
-
수석 연구원:
- Katharine Lewis, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Males or females, ≥ 18 years of age
-
Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confirmed CD19-positive if feasible
-
Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include:
- Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type)
- Follicular lymphoma (including duodenal-type follicular lymphoma)
- Mantle cell lymphoma
- B cell lymphomas not specified
-
If B cell NHL subtype likely to have bone marrow involvement must be willing to undergo bone marrow biopsy in the event of an on-study complete response to confirm response
-
NHL that is relapsed, refractory to, or intolerant of existing therapy(ies) with known curative potential, or for which no standard therapy is available; must have received at least 2 prior lines of systemic therapy
-
Must be in need of systemic treatment and not require immediate cytoreductive therapy
-
Part I: measurable or non-measurable disease
-
Part II: measurable disease according to The Revised Criteria/Lugano Classification
-
Part I: screening tumor biopsy requested, but optional; Part 2: patient must agree to screening tumor biopsy
-
ECOG performance status 0 or 1
-
Women of childbearing potential and fertile men agreeing to use two effective methods of contraception (including a highly effective method of contraception); women beginning 2 weeks prior to the first dose, men beginning prior to the first dose, and both continuing until 8 months after the last dose of study drug; male patients must also agree to refrain from sperm donation during this period.
-
Ability to understand and give written informed consent
Exclusion Criteria:
-
Women who are pregnant or intending to become pregnant before, during, or within 8 months after the last dose of study drug; women who are breastfeeding
-
Patients documented to be CD19-negative
-
Central nervous system (CNS) lymphoma, leptomeningeal infiltration, or spinal cord compression not controlled by prior surgery or radiotherapy; symptoms suggesting CNS involvement
-
Part 2: History of another malignancy within 2 years, with the exception of:
- Treated, non-melanoma skin cancers
- Treated carcinoma in situ (e.g., breast, cervix)
- Controlled, superficial carcinoma of the urinary bladder
- T1a or b prostate carcinoma treated according to standard of care, with PSA within normal limits
- Papillary thyroid carcinoma Stage I treated surgically for cure
-
Any of the following hematologic abnormalities at baseline (transfusion allowed > 5 days previous):
- Hemoglobin < 8.0 g/dL
- Absolute neutrophil count < 1,000 per mm3
- Platelet count < 75,000 per mm3
-
Any of the following laboratory abnormalities at baseline:
- Total bilirubin > 1.5 × upper limit of normal (ULN); > 3 × ULN if with Gilbert's Syndrome
- AST or ALT > 3 × ULN; > 5 × ULN if due to hepatic involvement by tumor
- Estimated GFR ≤ 60 mL/min corrected for BSA
- Albuminuria defined as urine albumin to creatinine ratio < 30 mg/g or < 3 mg/mmol) by spot urine albumin
-
Any of the following coagulation parameter abnormalities at baseline unless on a stable dose of anticoagulant therapy for a prior thrombotic event:
- PT or INR > 1.5 × ULN; > 3× ULN if anticoagulated)
- PTT > 1.5 × ULN; > 3× ULN if anticoagulated
-
Any of the following laboratory abnormalities at baseline aimed at assessing renal function:
- Estimated glomerular filtration rate (eGFR) ≤ 60 mL/min, corrected for BSA.
- Albuminuria defined as urine albumin to creatinine ratio (UACR) ≥ 45 mg/g or ≥ 4.5 mg/mmol by spot urine albumin
-
Patients with:
- Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks unless adequately treated and stable
- Active uncontrolled bleeding or a known bleeding diathesis
-
Significant cardiovascular disease or condition, including:
- Congestive heart failure or angina pectoris requiring therapy
- Ventricular arrhythmia requiring therapy or other uncontrolled arrhythmia
- Severe conduction disturbance (e.g., 3rd degree heart block)
- QTc interval ≥ 480 milliseconds
- Left ventricular ejection fraction below the lower limit of normal or < 50% by MUGA scan or echocardiogram
- Class III or IV cardiovascular disease according to the New York Heart Association Functional Classification
- History of acute coronary syndromes (e.g., MI, unstable angina), coronary angioplasty, stenting, or bypass within 6 months
-
Significant liver disease, including:
- Non-infectious hepatitis
- Hepatic cirrhosis (Child-Pugh Class B and Class C)
-
Significant pulmonary disease or condition, including:
- Significant symptomatic COPD, as assessed by the Investigator
- History or any current evidence on imaging studies of interstitial lung disease, pulmonary fibrosis
- History of pulmonary inflammatory disease, pneumonitis, ARDS
- History of pneumonia within 1 month
-
Significant corneal disease or condition, including history of or current evidence of keratitis
-
Clinically significant CNS disease or condition including PML, epilepsy, vasculitis, or neurodegenerative disease. Also including TIA or stroke within 6 months
-
Known HIV infection or AIDS
-
Active hepatitis B virus or hepatitis C virus infection
-
Any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 2 weeks
-
Autoimmune disease or condition requiring systemic steroids or other immunosuppressive medications
-
Unresolved Grade > 1 AE associated with any prior antineoplastic therapy (except persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, neutropenia, lymphopenia, hypomagnesemia, and/or endocrine end-organ failure being adequately managed by HRT)
-
Known or suspected hypersensitivity to any of the excipients of formulated study drug
-
Inadequate recovery from a surgical procedure, or a major surgical procedure within 4 weeks
-
Any other serious, life-threatening, or unstable preexisting medical condition, including significant organ system dysfunction, or clinically significant laboratory abnormality(ies)
-
A psychiatric disorder or altered mental status that would preclude understanding of the informed consent process
Drugs and Other Treatments to be Excluded:
-
Receipt of:
- Any CD19-targeted therapy within 4 weeks
- Any tumor vaccine within 6 weeks (must have progressed if previously received)
-
Prior autologous/allogeneic CAR-T therapy if known to be CD19-negative after
-
Any other antineoplastic agent for the primary malignancy without delayed toxicity within 3 weeks or 5 plasma half-lives, whichever is shortest (except nitrosoureas and mitomycin C within 6 weeks)
-
Any other investigational treatments within 3 weeks
-
Drugs known to impair renal function, including:
- NSAIDS within 3 days
- Aminoglycoside antibiotics, amphotericin B, etc. within 1 week
- Bisphosphonates within 1 month
-
Prior solid organ transplant
-
Allogeneic HSCT within 6 months, or:
- If receiving immunosuppression
- If with active evidence of GVHD
-
Autologous hematopoietic stem cell transplantation (HSCT) within 3 months
-
Radiotherapy:
- To target lesions within 4 weeks unless progression of the lesion has been documented
- To non-target lesions within 1 week
-
Live/live-attenuated vaccines against infectious diseases within 4 weeks
-
Immunosuppressive or systemic glucocorticoid therapy (> 10 mg prednisone daily or equivalent) within 2 weeks
-
Prophylactic use of hematopoietic growth factors within 1 week
-
Herbal therapies and supplements within 2 weeks
-
Strong inhibitors of cytochrome P450 within 2 weeks
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Dose Escalation Cohort (Part 1)
Each patient will receive repeat doses (by intravenous (IV) infusions) on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
실험적: Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
실험적: Dose Expansion: Follicular Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
실험적: Dose Expansion: Mantle Cell Lymphoma Participants
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
|
실험적: Dose Expansion: Other B cell lymphoma (B-NHL not otherwise specified [NOS])
Each patient will receive IKS03 at the RP2D defined in Part I on Day 1 of each 21-day cycle. Participants may continue on study until disease progression, unacceptable toxicity, or other withdrawal criterion is met. |
IKS03 is a human monoclonal antibody (Ab) targeting CD19 linked to a pyrrolobenzodiazepine (PBD) pro-drug as the cytotoxic agent. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Recommended Phase 2 Dose (Part I)
기간: Up to 20 months
|
RP2D will be determined using dose limiting toxicities (DLTs) and all other available study data |
Up to 20 months
|
|
Objective Response Rate (Part II)
기간: up to 42 months
|
Antineoplastic effects will be assessed by Criteria for Response Assessment: The Lugano Classification (Cheson 2014) |
up to 42 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Evaluation of the immunogenicity of IKS03 (Part I and II)
기간: Up to 42 months
|
Occurrence of ADA measured in serum at selected timepoints during the study |
Up to 42 months
|
|
Plasma Concentrations of IKS03 (Part I and II)
기간: Up to 42 months
|
Pharmacokinetic profile will be characterized by concentrations of IKS03 |
Up to 42 months
|
|
Determine recommended Phase 2 dose (RP2D) (Part II)
기간: Up to 42 months
|
Based on evidence of antitumor activity, acceptable tolerability, evidence of achieving target plasma concentration |
Up to 42 months
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Debra Wood, MD, Iksuda Therapeutics
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- IKS03-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .